Compare Dolby Laboratories, Inc. (DLB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Dolby Laboratories, Inc. trades at $48.49 (market cap $4.67B), while Vertex Pharmaceuticals Incorporated trades at $477.46 (market cap $121.89B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 26.1× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays a 2.86% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| DLB | VRTX | |
|---|---|---|
Market Cap | $4.67B | $121.89B |
Sector | Industrials | Health |
52-Week High | $76.79 | $529.59 |
52-Week Low | $48.51 | $366.54 |
Enterprise Value | $4.12B | $116.63B |
Dividend Yield | 2.86% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
